TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these infe...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy, Warren, Sarah, MacBeth, Kyle J., Meggendorfer, Manja, Haferlach, Torsten, Boettcher, Steffen, Ebert, Benjamin L., Al Ali, Najla H., Lancet, Jeffrey E., Cleveland, John L., Padron, Eric, List, Alan F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2020
Onderwerpen:
Myeloid Neoplasia
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731792/
https://ncbi.nlm.nih.gov/pubmed/32730593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006158
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items